A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone

Trial Profile

A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Cediranib (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms REGAL
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Nov 2016 This trial has been completed in France.
    • 07 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 23 Sep 2016 This trial was completed in Germany, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top